Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Conatumumab + Ganitumab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Conatumumab | AMG 655|AMG-655|AMG655 | Conatumumab (AMG 655) is a monoclonal antibody that binds to and activates the TRAIL receptor 2 (TR-2), initiating caspase activation and inducing tumor cell apoptosis (PMID: 24816908). | ||
| Ganitumab | AMG-479 | IGF-1R Inhibitor 17 | Ganitumab (AMG-479) is a recombinant antibody that binds to and inhibits IGF-1R. Inhibition of IGF-1R prevents activation of the downstream PI3K/Akt pathway, which may inhibit proliferation and induce apoptosis of tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|